New drug combo offers hope for head and neck cancer patients who Can't take chemo
NCT ID NCT05245682
First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 21 times
Summary
This early-phase study tests the safety of combining the experimental drug tolinapant with radiation therapy for people with head and neck cancer that has spread locally but hasn't been treated yet. Participants cannot take the standard chemotherapy drug cisplatin. The goal is to see if this combination is safe and feasible, and whether it can kill more cancer cells than radiation alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.